11月1日，博瑞医药获华西证券增持评级，近一个月博瑞医药获得5份研报关注。
研报预计博瑞医药2023-2025年营业收入分别为11.48/13.34/16.13亿元,预计2023-2025年EPS分别为0.57/0.69/0.89元。研报认为，博瑞医药业绩符合预期，公司持续加大研发投入，创新管线稳步拓展。
风险提示：创新药研发风险、产品被替代的风险、一致性评价、带量采购等政策影响的价格风险、宏观环境风险。
English
Back
- Markets
- Features
- News
- Community
- Learn
- Help Center
- About
- Offers & Rewards
- English
- 繁體中文
- 简体中文
- Dark
- Light
博瑞医药获华西证券增持评级，预测2023年年营业收入为11.48亿元
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.